SpotitEarly

What SpotitEarly does

SpotitEarly is a privately held medtech company developing a non-invasive, at-home breath-based pre-screening test for early cancer detection. Founded in 2020 by four Israeli founders with backgrounds spanning AI, K9 unit command, health technology, and special-technology operations, the company combines trained detection dogs (primarily beagles) with its proprietary LUCID Bio-AI Hybrid platform. The system detects cancer-related volatile organic compounds (VOCs) in breath samples; canines identify odor signatures while the LUCID AI collects and analyzes thousands of data points per second to verify and quantify the signals. Performance has been clinically validated in the Rainbow Study (1,386 participants across three Israeli medical centers), which was published in Nature Scientific Reports and reported 93.9% sensitivity and 94.3% specificity across four major cancer types (breast, lung, colorectal, prostate), with 94.8% sensitivity for early-stage (Stage 0–2) disease and 81.8% sensitivity for 14 additional cancer types outside the training panel.

The company's core product, the SpotitEarly Cancer Pre-Screening Test, is positioned as a non-invasive, at-home alternative or complement to mammography, colonoscopy, low-dose CT, and PSA testing. It is supported by a BRCA Germline Testing add-on for hereditary cancer risk assessment and by an at-home breath collection kit shipped to a CLIA-registered laboratory. The product is not yet commercially available; commercial launch is targeted for 2027 in the U.S. market via a direct-to-consumer online subscription. To date, the company has been funded primarily through a $6.2M seed round (June 2022), a $20.3M raise in May 2025, and a Regulation A+ public offering at $7.15 per share. Strategic clinical partnerships with Fox Chase Cancer Center (lung cancer, equity-stake collaboration announced January 2026) and Hackensack Meridian Health's Hennessy Institute (PINK Study, a 2,000-participant U.S. breast cancer trial announced September 2025) anchor its U.S. clinical and commercial entry. The U.S. headquarters and CLIA-registered lab are based in New Jersey, with R&D roots in Israel, a team of approximately 50–60 members across AI, biotech, canine operations, clinical research, and regulatory affairs, and recognition including TechCrunch Startup Battlefield 200 and the 2026 Fierce Healthcare Fierce 15.

Name

SpotitEarly

Legal name

SpotitEarly Ltd.

Website

https://spotitearly.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

SpotitEarly is a pre-revenue medtech company developing an at-home breath-based cancer pre-screening test that combines trained detection dogs with its proprietary LUCID Bio-AI platform to detect four major cancers (breast, lung, colorectal, prostate) plus 14 additional types, targeting a U.S. consumer subscription launch in 2027.

Ownership category

akta.pro rank

Product category

Cancer Screening Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI), Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection) (HLAHAOAF), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Cancer screening services
• Breath diagnostics
• Multi-cancer detection
• Non-invasive testing
• Bio-AI diagnostics

Headquarters

HQ city

Englewood

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. At-Home Cancer Screening Test: Direct-to-consumer breath-based cancer screening test sold via online subscription model. Users subscribe to receive at-home breath collection kits and submit samples for analysis. Commercial launch targeted for 2027 in the U.S. market.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

SpotitEarly offers a non-invasive at-home breath-based cancer pre-screening test that combines trained detection dogs with its proprietary LUCID Bio-AI Hybrid Platform to analyze volatile organic compounds (VOCs) in breath samples. The test screens for four major cancer types (breast, colorectal, lung, and prostate) plus 14 additional cancer types from a single breath sample, with reported 94% sensitivity and specificity in early-stage detection. Samples are collected at home via a breath collection kit and mailed to a CLIA-registered laboratory for analysis, with planned U.S. commercial rollout via online subscription in 2027.

Product overview

SpotitEarly offers a unified cancer pre-screening platform centered on its proprietary LUCID Bio-AI Hybrid platform, which combines trained detection dogs' olfactory capabilities with artificial intelligence to detect cancer-related volatile organic compounds in breath samples. The core offering is the SpotitEarly Cancer Pre-Screening Test, a non-invasive at-home breath test targeting four major cancers (breast, colorectal, lung, and prostate) with demonstrated 94% accuracy. The company also provides BRCA Germline testing as an add-on genetic screening module for hereditary cancer risk assessment. The LUCID platform serves as the technological backbone, collecting and analyzing detection data to power the screening products.

Differentiator

Problem solved

Functional benefit

Brands

• LUCID: Proprietary Bio-AI Hybrid platform that combines trained detection dogs with AI to analyze breath samples for cancer detection. LUCID collects and analyzes thousands of data points every second, providing verification regarding canine detection signals.

Products and services

• Cancer Pre-Screening Test An at-home breath-based cancer pre-screening test that uses trained detection dogs and AI to analyze a single breath sample for early detection of breast, colorectal, lung, and prostate cancer. Demonstrated 94% sensitivity and specificity in early-stage cancer detection (Stages 0-2). Non-invasive, no blood draw, no radiation, no clinic visit required; samples mailed to a CLIA-registered laboratory for analysis.
• BRCA Germline Testing Genetic screening service for BRCA gene mutations providing additional cancer risk assessment alongside the breath-based pre-screening test. Enables comprehensive pre-screening for hereditary cancer risk.
• LUCID Bio-AI Hybrid Platform Proprietary Bio-AI Hybrid technology platform integrating hardware devices and software to collect and analyze thousands of data points per second from trained detection dogs. LUCID provides verification of canine detection signals, optimized interpretation, validated conclusions, and adaptive calibration; processes each sample in under one second. Serves as the technological backbone for SpotitEarly's pre-screening tests and is positioned for clinical deployment via screening centers.

Quantifiable outcome

• 94% sensitivity and specificity in early-stage cancer detection (Stages 0-2)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Fox Chase Cancer CentercoreStrategic or Co-development Partner · 22 January 2026Strategic partnership for multi-year clinical trials evaluating breath-based cancer detection test in patients with suspected lung cancer. Fox Chase received equity stake in SpotitEarly. Collaboration aims to generate high-quality clinical evidence supporting regulatory pathways and U.S. commercialization.
• Hackensack Meridian HealthcoreStrategic or Co-development Partner · 30 September 2025Research partnership to launch the PINK Study, a 2,000-participant U.S. clinical trial focused on breath-based breast-cancer screening. Partnership with The Hennessy Institute at Hackensack Meridian Health for participant enrollment in New Jersey.
• University of PennsylvaniacoreStrategic or Co-development PartnerClinical partner for Rainbow Study - large-scale observational double-blind clinical performance trial. One of three Israeli medical centers participating in initial clinical validation.
• Sheba Tel-HaShomer Medical CentercoreStrategic or Co-development PartnerClinical partner for Rainbow Study and key publications. Prof. Eitan Friedman from Sheba serves on Scientific Advisory Board.
• Tel Aviv Sourasky Medical CentercoreStrategic or Co-development PartnerClinical partner for Rainbow Study. Prof. Nadir Arber, Head of Integrated Cancer Prevention Center, has endorsed SpotitEarly technology.
• Rambam Health Care CampusminorStrategic or Co-development PartnerClinical partner for Rainbow Study clinical trial.
• Hadassah Medical CenterminorStrategic or Co-development PartnerClinical partner. Prof. Vivian Barak, Head of Immunology & Tumor Diagnosis Lab, serves on Scientific Advisory Board.
• Assuta - Private hospitals networkminorStrategic or Co-development PartnerClinical partner for Rainbow Study.
• University City Science CenterminorStrategic or Co-development PartnerClinical partner for Rainbow Study.
• Midgam Research Bio BankminorStrategic or Co-development PartnerResearch partner for clinical trial sample management.
• Manhattan Street CapitalcoreChannel Partner/ Reseller/ DistributorSEC-compliant funding platform acting as regulated offering partner for Regulation A+ public offering. Processes investments via secure online portal.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GRAIL: GRAIL's Galleri test is a leading multi-cancer early-detection blood test for asymptomatic adults. SpotitEarly and GRAIL compete for the same at-home / direct-to-consumer multi-cancer screening opportunity, though they use different modalities (breath + canine-AI vs. cell-free DNA methylation).
• Owlstone Medical: Owlstone Medical develops breath biopsy diagnostics for cancer and other diseases using VOC analysis. It is the most direct breath-based cancer detection peer to SpotitEarly, addressing the same biomarker class (VOCs in breath) with a non-canine technology stack.

Broad incumbents

• Exact Sciences: Exact Sciences markets Cologuard for colorectal cancer screening and acquired Thrive Earlier Detection for multi-cancer screening. As the established leader in non-invasive at-home cancer screening, it is a broad incumbent and key competitive benchmark for SpotitEarly's go-to-market.
• Guardant Health: Guardant Health is a leading oncology diagnostics company using liquid biopsy to detect cancer through blood samples. It competes in the multi-cancer detection space with established CLIA lab infrastructure, FDA-approved tests, and commercial channels relevant to SpotitEarly's target market.
• Philips (Oncology / Breath Research): Philips has invested in research around electronic-nose / breath-analysis for lung disease and cancer, and is a broad incumbent medical device and diagnostics player that could compete in or partner around breath-based cancer screening if the category matures.

Emerging players

• Freenome: Freenome is developing a multiomics blood-based test for early cancer detection, including colorectal and multi-cancer screening. It is an emerging player in the same multi-cancer early-detection category as SpotitEarly, focused initially on colorectal cancer with a non-imaging, blood-based platform.
• Thrive Earlier Detection: Thrive Earlier Detection (acquired by Exact Sciences) developed CancerSEEK, a multi-cancer blood-based screening test. It is a relevant prior-art comparable in the multi-cancer screening category even though it is now part of Exact Sciences.
• Biological Dynamics: Biological Dynamics is developing a blood-based platform for early cancer detection. While modality differs (blood vs. breath), it competes in the same early-detection, multi-cancer diagnostic market.
• Universal Diagnostics: Universal Diagnostics is developing a blood-based multi-cancer screening test using methylation and other biomarkers. It is an emerging peer pursuing the same broad multi-cancer early-detection opportunity as SpotitEarly, with a complementary but competing technology approach.
• Nucleix: Nucleix develops blood-based liquid biopsy tests for early lung cancer detection using methylation markers. It overlaps with SpotitEarly's lung cancer focus and serves as an emerging peer in non-invasive cancer screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/spot_it_early
• YouTubeyoutube.com/channel/UCbdLqTUCUi1REcEYoiOx8SQ
• Facebookfacebook.com/SpotItEarly
• LinkedInlinkedin.com/company/spotitearly
• Instagraminstagram.com/spotitearly
• TikToktiktok.com/@spotitearly

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpotitEarly